Evidence map›Paper›PMID 41091287›Full record

ArticleJournal of neuro-oncology2025

Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.

Alexander Yuile, Joe Q Wei, Kelly J McKelvey, Emily K Colvin, Razia Zakarya, Shihani P Stoner, Advaitha Jagadeesan, Madiha Yunus, Hasanthi C de Silva, Josef Gilson and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Alexander YuileBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Joe Q WeiNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
Kelly J McKelveyBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Emily K ColvinBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Razia ZakaryaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Shihani P StonerBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Advaitha JagadeesanBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Madiha YunusBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Hasanthi C de SilvaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Josef GilsonBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Lionel LeckBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Laila ArzumanBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Otto ZhangDepartment of Medical Oncology, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Meredith OatleyDepartment of Medical Oncology, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Nick PavlakisBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
David I ChanBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Malinda ItchinsBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Marina KastelanThe Brain Cancer Group, North Shore Private Hospital, St. Leonards, NSW, 2065, Australia.
Adrian LeeBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Helen R WheelerBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Alexander MenziesNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
Connie I DiakosBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Alexander GuminskiNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
Michael BackNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
Thomas EadeNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
Dasantha JayamanneNorthern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
Andrew KneeboneDepartment of Radiation Oncology, School of Life Sciences, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.
Amanda L HudsonBill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia. amanda.hudson@sydney.edu.au.ORCID http://orcid.org/0000-0002-8275-0395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGliomas are the most common primary brain malignancy in adults, with treatment advances limited by challenges like the blood-brain barrier, tumour heterogeneity, and an immunosuppressive microenvironment. Tumour vaccines, such as adenoviral vector and mRNA-based vaccines, may overcome these barriers, but the ability of glioma patients to mount an immune response to these therapies remains unclear. This study assesses immune responses to adenoviral DNA and mRNA-based COVID-19 vaccinations in a glioma-enriched population as a model for glioma-based vaccine therapies.

methodsCOVID-19 naïve glioma and non-glioma solid tumour patients, along with healthy volunteers, were recruited between May 2021 and December 2022. Blood samples were collected at various time points: pre-vaccination, between the first and second doses, and at 1-, 3-, and 4-6-months post 2nd vaccination, including after a third booster dose. SARS-CoV-2 specific immune responses were evaluated using ELISA and ELISPOT assays.

resultsA total of 91 participants were analysed. At 1-month post 2nd vaccination, no significant differences in seroconversion rates were observed. By 3 months, glioma and non-glioma patients had significantly lower rates compared to healthy volunteers. Memory B and T cell responses were similar between glioma patients and healthy volunteers, but non-glioma patients showed decreased responses. Vaccine efficacy was comparable across all cohorts.

conclusionThis study demonstrates that glioma patients can mount meaningful immune responses to DNA and mRNA vaccines, suggesting that glioma-based vaccine therapies are feasible and warrant further exploration.

Indexed as

Brain NeoplasmsCancer VaccinesCOVID-19COVID-19 VaccinesGliomaAdultAgedFemaleHumansMaleMiddle AgedSARS-CoV-2Cancer VaccinesCOVID-19 VaccinesCOVID-19GliomaImmune responseVaccinations

Identifiers

PMID41091287
PMCPMC12528327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.